The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rising Costs of Biologics in the U.S. Suggest Need for Negotiation Ability

Rising Costs of Biologics in the U.S. Suggest Need for Negotiation Ability

May 21, 2015 • By Rob Goodier (Reuters Health)

  • Tweet
  • Email
Print-Friendly Version / Save PDF

The costs of some disease-modifying therapies outpace prescription drug inflation, saddling insured patients with thousands of dollars in out-of-pocket payments and delayed or denied coverage, two new studies have shown.

You Might Also Like
  • Unwelcome News about Medicare’s Rising Drug Plan Costs
  • Can Anything Contain Drug Costs in the U.S.?
  • Rising Administrative Costs Pinch Rheumatologists’ Bottom Line

Disease-modifying therapies for multiple sclerosis are rising in cost five to seven times faster than inflation and cost more in the United States than in foreign markets, according to a study by Dr. Daniel Hartung and colleagues at Oregon Health and Science University in Portland, published online April 24 in Neurology.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

And Medicare patients with Part D drug coverage pay an average of more than $2700 before taking on 5% copays for biologic drugs that treat rheumatoid arthritis, according to a study by Dr. Jinoos Yazdany and colleagues at the University of California, San Francisco, published April 21 in Arthritis & Rheumatology.

The separate findings suggest a single solution, that Medicare should be allowed to negotiate drug prices with pharmaceutical manufacturers, experts say.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“Costs of drugs for arthritis are escalating for the same reason drugs for MS are going up and up in Medicare, both resulting from the ridiculous legislation that prevents Medicare negotiating with the pharmaceutical industry on costs of drugs,” Dr. Jock Murray, professor emeritus at Dalhousie University in Nova Scotia, Canada, who cowrote an editorial that accompanies the MS paper in Neurology, told Reuters Health by email.

“When they can’t negotiate, the pharmaceutical industry can, without justification, increase costs as high as they like. And they like high costs,” Dr. Murray says.

Nearly all Medicare Part D drug-coverage plans require prior authorization and a coinsurance payment that amounts to an average of nearly 30% of the cost of biologic RA drugs, according to Dr. Yazdany’s analysis of more than 2700 formularies in all 50 states and Washington, D.C. That burdens patients with an average out-of-pocket payment of $2700 before hitting a cap. Then patients pay 5% of the drug costs.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

By comparison, six out of nine non-biologic RA drugs studied were covered without prior authorization at fixed copayments averaging $10 or less per month.

First-generation MS biologics cost $8000 to $11,000 per year when they were released in the 1990s, and now they cost about $60,000 per year, Dr. Hartung has found. Next-generation biologics cost even more, typically by as much as 25-60%.

First-generation drug prices have risen even as next-generation drugs have entered the market as competition. Competition usually lowers prices, however. And these drugs actually do cost less in foreign countries, implying that the manufacturers have inflated the prices in the United States, the researchers write.

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, DMARDs & Immunosuppressives, Drug Updates Tagged With: Biologics, cost, Drugs, Medicare, Multiple Sclerosis, Research, Rheumatoid arthritis

You Might Also Like:
  • Unwelcome News about Medicare’s Rising Drug Plan Costs
  • Can Anything Contain Drug Costs in the U.S.?
  • Rising Administrative Costs Pinch Rheumatologists’ Bottom Line
  • U.S. to Boost Drug Price Negotiation in Medicare Advantage Health Plans

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.